SCHEMBL162572

SCHEMBL162572

COC(=O)C1CCC(c2ncc(-c3ccc(NC(=O)Nc4ccccc4Cl)cc3)o2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.49
TP53 P04637 7/20 0.49
MAPT P10636 7/20 0.49
KMT2A Q03164 5/20 0.49
POLB P06746 3/20 0.49
DGAT1 O75907 2/20 0.46
MEN1 O00255 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CYP2C9 P11712 1/20 0.44
HDAC4 P56524 1/20 0.44
NPC1 O15118 4/20 0.44
TEK Q02763 1/20 0.43
RAB9A P51151 3/20 0.43
NOD2 Q9HC29 1/20 0.43
KDR P35968 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163647 0.90 KMT2A (0.54) LMNATP53MAPTKMT2ACYP2C9
SCHEMBL161688 0.90 DGAT1 (0.51) LMNATP53MAPTKMT2ADGAT1
SCHEMBL161754 0.90 DGAT1 (0.57) LMNATP53MAPTKMT2APOLB
SCHEMBL174380 0.90 TP53 (0.52) LMNATP53MAPTKMT2APOLB
SCHEMBL161847 0.86 NPC1 (0.49) LMNATP53MAPTKMT2APOLB
SCHEMBL163130 0.86 SMO (0.58) LMNATP53MAPTKMT2APOLB
SCHEMBL165013 0.83 DGAT1 (0.59) LMNATP53MAPTKMT2ADGAT1
SCHEMBL406879 0.82 CYP2C9 (0.56) LMNATP53MAPTKMT2APOLB
SCHEMBL408805 0.82 CYP2C9 (0.56) LMNATP53MAPTKMT2APOLB
SCHEMBL162433 0.80 NPC1 (0.57) LMNATP53MAPTKMT2ADGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 LMNA 2076/4885TP53 1654/4885MAPT 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.